References
- 1. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmaco. 2005; 69:541-50.
- 2. Akgür SA, Oztürk P, Solak I, Moral AR, Ege B. Human serum paraoxonase (PON1) activity in acute organophosphorus insecticide poisoning. Forensic Sci Int. 2003; 133:136-40.
- 3. Rochu D, Chabriere E, Masson P. Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology. 2007; 233:47-59.
- 4. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 2000; 101:252-7.
- 5. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca, S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer. 2007; 7:48-56.10.1186/1471-2407-7-48
- 6. Mackness MI. Why plasma should not be used to study paraoxonase. Atherosclerosis. 1998; 136:195-6.
- 7. Draganov DI, Teiber JF, Audrey S, Yoichi O, Roger S, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005; 46:1239-47.10.1194/jlr.M400511-JLR200
- 8. Clarimon J, Eerola J, Hellström O, Tienari PJ, Singleton AP. Paraoxonase 1 gene polymorphisms and Parkinson’s disease in a Finnish population. Neurosci Lett. 2004; 367:168-70.
- 9. Kondo I, Mitsutoshi Y. Genetic polymorphism of paraoxonase 1 and susceptibility to Parkinson’s disease. Brain Res. 1998; 806:271-3.
- 10. Cellini E, Tedde A, Bagnoli S, Nacmia B, Piacentini S, Bessi V. Association analysis of the paraoxonase-1 gene with Alzheimer’s disease. Neurosci Lett. 2006; gene with the risk of developing Alzheimer’s disease. Neurobiol Aging. 2006; 27:1212-5.
- 11. Chapuis J, Boscher M, Bensemain F, Cottel D, Amouyel P, Lambert JC. Association study of the paraoxonase1
- 12. Kalmar T, Seres I, Balogh Z, Kaplar G, Paragh G. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metab. 2005; 31:574-80.
- 13. Ikeda Y, Inoue M, Suehiro T, Arii K, Kumon Y, Hashimoto K. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol. 2009; 46:239-42.
- 14. Gugliucci A, Mehlhalf K, Kinugasa E, Ogata H, Schulze K, Kimura S. Paraoxonase1 concentrtions in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adducts clearance. Clin Chim Acta. 2007; 377:213-20.
- 15. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998; 9: 2082-8.
- 16. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics. 2006; 16:183-90.
- 17. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000; 28: 1335-42.
- 18. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol. 2009; 235:1-9.10.1016/j.taap.2008.11.001
- 19. Marsillach J, Ferré N, Vila MC, Lligona A, Mackness B, Mackness M, et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem. 200; 740:645-50.
- 20. Ferre N, Camps J, Marsillach J, Mackness B, Mackness M, Coll B, Tous M, Joven J. Comparison of paraoxonase 1 measurements in serum and in lithium-heparinanticoagulated plasma samples. Clin Chem. 2005; 51: 922-3.10.1373/clinchem.2005.048231
- 21. Huen K, Richter R, Furlong C, Eskenazi B, Holland N. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta. 2009; 402:67-4.
- 22. Charlton-Menysa V, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem. 2006; 52:453-7.10.1373/clinchem.2005.063412
- 23. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat Struct Mol Bio. 2004; 11: 412-9.10.1038/nsmb767
- 24. Rochu D, Renault F, Elias M, CleryBarraud C, Chabriere E, Masson P. Stability of highly purified human paraoxonase: Association with human phosphate binding protein is essential for preserving its active conformation(s). Biochim Biophys Acta. 2007; 1774: 874-83. 408:199-02.